Jay Venkatesan insider trades
Open-market stock purchases and sales by Jay Venkatesan, Director at Elicio Therapeutics, Inc, from SEC Form 4 filings since Nov 18, 2013.
Track record: 0% of 4 scored buys are up 5% or more since purchase, averaging -46%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Aug 31, 2026 | ELTX Elicio Therapeutics, Inc | Bought (not open market) | — |
| Jun 17, 2026 | SER Serina Therapeutics, Inc | Bought (not open market) | $504K |
| Jun 17, 2026 | SER Serina Therapeutics, Inc | Bought (not open market) | — |
| Jun 17, 2026 | SER Serina Therapeutics, Inc | Bought (not open market) | $217K |
| May 22, 2026 | SER Serina Therapeutics, Inc | Bought | $1K |
| Mar 31, 2026 | SER Serina Therapeutics, Inc | Bought (not open market) | $14.7K |
| Nov 7, 2025 | SER Serina Therapeutics, Inc | Bought (not open market) | — |
Companies traded
- ELTX Elicio Therapeutics, Inc: 2 buys, last Aug 31, 2026
- SER Serina Therapeutics, Inc: 1 buy, last Jun 17, 2026
- ALPN Alpine Immune Sciences, Inc: 2 buys, 1 sale, last Jul 15, 2022
- ANGN Angion Biomedica Corp: 9 buys, 2 sales, last May 25, 2022
- XCUR Exicure, Inc: 2 buys, last Jul 6, 2020
- LBIO Lion Biotechnologies, Inc: other filings, last Jun 1, 2017
- ONTY Oncothyreon Inc: 1 buy, last Dec 16, 2014